Xác định mối quan hệ cấu trúc-hoạt tính in vitro của 30 chất kích thích tâm thần mới bằng phương pháp thu nhận β-arrestin 2 đến thụ thể serotonin 2A

Blaazer AR, Smid P, Kruse CG (2008) Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. ChemMedChem 3(9):1299–1309. https://doi.org/10.1002/cmdc.200800133 Braden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe 339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70(6):1956–1964. https://doi.org/10.1124/mol.106.028720 Canal CE (2018) Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. Handb Exp Pharmacol 252:227–260. https://doi.org/10.1007/164_2018_107 Cannaert A, Franz F, Auwarter V, Stove CP (2017) Activity-based detection of consumption of synthetic cannabinoids in authentic urine samples using a stable cannabinoid reporter system. Anal Chem 89(17):9527–9536. https://doi.org/10.1021/acs.analchem.7b02552 Cannaert A, Storme J, Franz F, Auwarter V, Stove CP (2016) Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Anal Chem 88(23):11476–11485. https://doi.org/10.1021/acs.analchem.6b02600 Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol Off J Am Coll Med Toxicol 9(2):172–178. https://doi.org/10.1007/s13181-013-0295-x Dixon AS, Schwinn MK, Hall MP et al (2016) NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem Biol 11(2):400–408. https://doi.org/10.1021/acschembio.5b00753 Elmore JS, Decker AM, Sulima A et al (2018) Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142:240–250. https://doi.org/10.1016/j.neuropharm.2018.02.033 EMCDDA-Europol (2014) EMCDDA–Europol Joint Report on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe). https://www.emcdda.europa.eu/publications/joint-report/25I-NBOMe_en. Accessed Apr 2020 EMCDDA (2004) Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs. https://www.emcdda.europa.eu/publications/risk-assessments/2C-I-2C-T-2-2C-T-7_fr. Accessed Apr 2020 Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27–34. https://doi.org/10.1016/j.bcp.2018.09.024 Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD (2019) Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs. Neuropharmacology 144:368–376. https://doi.org/10.1016/j.neuropharm.2018.10.037 Hansen M, Phonekeo K, Paine JS et al (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem Neurosci 5(3):243–249. https://doi.org/10.1021/cn400216u Hondebrink L, Zwartsen A, Westerink RHS (2018) Effect fingerprinting of new psychoactive substances (NPS): what can we learn from in vitro data? Pharmacol Ther 182:193–224. https://doi.org/10.1016/j.pharmthera.2017.10.022 Iwersen-Bergmann S, Lehmann S, Heinemann A et al (2019) Mass poisoning with NPS: 2C-E and bromo-DragonFly. Int J Legal Med 133(1):123–129. https://doi.org/10.1007/s00414-018-1882-9 Jensen AA, McCorvy JD, Leth-Petersen S et al (2017) Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of n-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther 361(3):441–453. https://doi.org/10.1124/jpet.117.239905 Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019) Receptor interaction profiles of 4-alkoxy-substituted 2,5-dimethoxyphenethylamines and related amphetamines. Front Pharmacol 10:1423. https://doi.org/10.3389/fphar.2019.01423 Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304(1):229–237. https://doi.org/10.1124/jpet.102.042184 Kyriakou C, Marinelli E, Frati P et al (2015) NBOMe: new potent hallucinogens–pharmacology, analytical methods, toxicities, fatalities: a review. Eur Rev Med Pharmaco 19(17):3270–3281 Leth-Petersen S, Petersen IN, Jensen AA et al (2016) 5-HT2A/5-HT2C receptor pharmacology and intrinsic clearance of n-benzylphenethylamines modified at the primary site of metabolism. ACS Chem Neurosci 7(11):1614–1619. https://doi.org/10.1021/acschemneuro.6b00265 Lopez-Gimenez JF, Gonzalez-Maeso J (2018) Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci 36:45–73. https://doi.org/10.1007/7854_2017_478 Luethi D, Liechti ME (2018) Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int J Neuropsychopharmacol 21(10):926–931. https://doi.org/10.1093/ijnp/pyy047 Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects. Arch Toxicol. https://doi.org/10.1007/s00204-020-02693-7 Luethi D, Trachsel D, Hoener MC, Liechti ME (2018) Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology 134(Pt A):141–148. https://doi.org/10.1016/j.neuropharm.2017.07.012 Luethi D, Widmer R, Trachsel D, Hoener MC, Liechti ME (2019) Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives). Eur J Pharmacol 855:103–111. https://doi.org/10.1016/j.ejphar.2019.05.014 Moya PR, Berg KA, Gutierrez-Hernandez MA et al (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321(3):1054–1061. https://doi.org/10.1124/jpet.106.117507 Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002 Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264–355. https://doi.org/10.1124/pr.115.011478 Nichols DE (2018) Chemistry and structure-activity relationships of psychedelics. Curr Top Behav Neurosci 36:1–43. https://doi.org/10.1007/7854_2017_475 Noble C, Holm NB, Mardal M, Linnet K (2018) Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A. Toxicol Lett 295:397–407. https://doi.org/10.1016/j.toxlet.2018.07.018 Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (1998) A novel (benzodifuranyl) aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 41(26):5148–5149. https://doi.org/10.1021/jm9803525 Parrish JC, Braden MR, Gundy E, Nichols DE (2005) Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem 95(6):1575–1584. https://doi.org/10.1111/j.1471-4159.2005.03477.x Pottie E, Cannaert A, Van Uytfanghe K, Stove CP (2019) Setup of a serotonin 2A receptor (5-HT2AR) bioassay: demonstration of its applicability to functionally characterize hallucinogenic new psychoactive substances and an explanation why 5-HT2AR bioassays are not suited for universal activity-based screening of biofluids for new psychoactive substances. Anal Chem 91(24):15444–15452. https://doi.org/10.1021/acs.analchem.9b03104 Pottie E, Tosh DK, Gao ZG, Jacobson KA, Stove CP (2020) Assessment of biased agonism at the A3 adenosine receptor using beta-arrestin and miniGalphai recruitment assays. Biochem Pharmacol 177:113934. https://doi.org/10.1016/j.bcp.2020.113934 Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL (2019) DARK classics in chemical neuroscience: NBOMes. ACS chemical neuroscience. https://doi.org/10.1021/acschemneuro.9b00528 Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546–553. https://doi.org/10.1016/j.neuropharm.2015.08.034 Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 26(8):1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001 Shulgin A, Shulgin A (1991) PiHKAL: a chemical love story. Transform Press, Berkley, CA Suzuki J, Dekker MA, Valenti ES et al (2015) Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56(2):129–139. https://doi.org/10.1016/j.psym.2014.11.002 UNODC (2020) Current NPS threats. https://www.unodc.org/unodc/en/scientists/current-nps-threats.html. Accessed Apr 2020 Vasudevan L, Vandeputte M, Deventer M, Wouters E, Cannaert A, Stove CP (2020) Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Biochem Pharmacol 177:113910. https://doi.org/10.1016/j.bcp.2020.113910 Wacker D, Wang S, McCorvy JD et al (2017) Crystal structure of an LSD-bound human serotonin receptor. Cell 168(3):377–389. https://doi.org/10.1016/j.cell.2016.12.033 Wouters E, Walraed J, Banister SD, Stove CP (2019) Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochem Pharmacol 169:113623. https://doi.org/10.1016/j.bcp.2019.08.025 Wouters E, Walraed J, Robertson MJ et al (2020) Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacol Translat Sci 3(2):285–295. https://doi.org/10.1021/acsptsci.9b00069